Divis Laboratories Ltd

- There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript. - The management discusses ongoing and planned capex and investments, highlighting strategic, planned expansion without indicating a need for new fundraising. - Capex guidance for FY26 is increasing beyond ₹2,000 crores, and spending is being carefully planned and spread across multiple units. - Cash on books is ₹3,451 crores as of September 30, 2025, indicating strong liquidity. - No comments or indications about raising funds via equity or debt were made during the call. - The company focuses on long-term investments supported by existing resources and partnerships, rather than external capital raising.

- Divi's Laboratories is executing three major capex programs focused on new technologies, capacity expansion, and key strategic projects. - Capex is strategically planned and spread across all three production units, not concentrated in one. - Capex guidance for FY26 was initially ₹2,000 crores, with ₹1,550 crores spent in H1; FY26 capex expected to be higher than ₹2,000 crores. - Further investments will be aligned with long-term contracts and regulatory approvals, expected to start contributing revenues in 1-2 years. - Ongoing construction of production blocks in Unit 3 for key starting materials; additional blocks to be built as needed on available land. - Investments are being made in peptide manufacturing capacities and advanced technologies like flow chemistry, biocatalysis, and green chemistry. - Divi's sees a positive outlook for capex and growth in the next 1-2 years, aligned with their strategy to become a global leader in peptides and complex APIs.

- The company has a healthy project pipeline, with multiple projects at different milestones; outcomes expected in next 1-2 years. - Revenue growth driven by a mix of generic and custom synthesis (CS) businesses; CS currently contributing a larger share (~55%). - Continued volume stability in the generic business despite pricing pressures; no customer or capacity loss reported. - New generics coming off patent are expected to add volume and revenue. - Custom synthesis business growth supported by advancing projects, including peptides and late-life cycle management; three major capex programs underway to expand capacity. - Peptide segment showing strong momentum with investments scaling up alongside customer regulatory progress. - Nutraceutical business is evolving as a key growth driver. - Constant currency revenue growth for H1FY26 is around 10.79%; full-year growth expected in a similar range. - Overall positive outlook for revenue growth in next 1-2 years, supported by strategic investments and new product launches.

- Divi's Laboratories anticipates positive growth in the next 1-2 years driven by new product launches, especially generics coming off patents, and growth in contract synthesis (CS) business (Pages 9, 16). - The three new dedicated custom synthesis projects expected to start from Q4 FY27 should contribute to near-term and medium-term growth (Page 10). - While generic segment faces pricing pressure, volumes remain stable, supported by backward integration, with hopes that pricing erosion will stabilize in upcoming quarters (Pages 6, 13, 16). - Earnings growth will be influenced by product mix between generics (45%) and CS (55%), with CS showing relatively better margins, but overall margin upside is limited due to ongoing generic pricing pressure (Pages 9, 16). - Capex investments are strategically planned to support capacity expansion aligned with long-term contracts, enabling sustainable growth (Pages 7, 8). - Management is hopeful about positive earnings outcomes from late-stage projects and sustainable contracts (Pages 12, 16).

- The company has a strong and healthy pipeline of projects currently in various phases, including equipment installation, qualification, and validation. - Revenues from the announced projects are expected to begin entering the books within the next 1 to 2 years, subject to regulatory approvals. - Divi’s has several ongoing customer projects and long-term contracts that guide their investments and production schedules. - Specific order book figures or the total value of pending orders were not disclosed due to confidentiality agreements. - Management emphasized the robustness of the pipeline and their readiness to scale capacity as needed, supported by multiple production blocks and available land for future expansion.